• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Mankind Pharma Ltd.
    11 Jul 2025, 07:52AM
    2579.60
    -0.75%
    Mankind Pharma Gets Target Price Hike Why Jefferies Calls It Top Pick
    Mankind Pharma Gets Target Price Hike Why Jefferies Calls It Top Pick
    NDTV Profit
    Jefferies anticipates that the first and second quarters will be pivotal for Mankind Pharma, with India Rx growth normalising in the second half of the fiscal.
    Copy LinkShare onShare on Share on Share on
    Mankind Pharma Ltd. has an average target of 2840.50 from 2 brokers.
    Stock Market Live Updates 11 July 2025: Stock to buy today: Mankind Pharma
    Business Line | 11 Jul 2025, 06:36AM 2 more
    Today's Stock Recommendation: July 11, 2025
    Business Line | 11 Jul 2025, 06:30AM
    Stock to buy today: Mankind Pharma (2,543) BUY
    Business Line | 11 Jul 2025, 06:30AM
    logo
    Shilpa Medicare Ltd.
    10 Jul 2025
    Dividend
    827.60
    -1.08%
    Here's why Shilpa Medicare share price is buzzing in trade today; details
    Business Standard
    Shilpa Medicare shares rose today after the company secured GMP certification from Saudi Arabia's SFDA for its Unit VI facility in Dabaspet, Bengaluru.
    Copy LinkShare onShare on Share on Share on
    Shilpa Medicare Ltd. is trading above its 200 day SMA of 786.3
    logo
    Emcure Pharmaceuticals Ltd.
    10 Jul 2025
    1348.90
    -2.02%
    Emcure Pharma rises over 2% as USFDA issues Form 483 with Zero observations
    Business Standard
    Emcure Pharma share price rose in trade after the company announced that United States Food and Drug Administration (USFDA) issued Form 483 with zero observations for its Sanand, Ahmedabad unit.
    Copy LinkShare onShare on Share on Share on
    Emcure Pharmaceuticals Ltd. has gained 42.67% in the last 6 Months
    logo
    Lupin Ltd.
    10 Jul 2025
    2043.40
    2.79%
    Lupin, Zentiva Group ink agreement to commercialise biosimilar Certolizumab Pegol
    Business Line
    Both parties will invest in the development of the new biosimilar
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.
    logo
    Lupin Ltd.
    09 Jul 2025
    2043.40
    2.79%
    Lupin share pops 2% on licencing and supply agreement with Zentiva; details
    Business Standard
    Lupin's share price rose in trade today after the company announced a licensing and supply agreement with Zentiva, k.s., for the commercialisation of its biosimilar Certolizumab Pegol.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.
    logo
    Laurus Labs Ltd.
    09 Jul 2025
    896.05
    0.05%
    Glenmark, Laurus Lab: Will Trump's 200% tariff threat derail pharma stocks?
    Business Standard
    Donald Trump threatens of a potential 200% tariff on pharma imports; can this derail the rally in pharma shares, which have gained up to 50% in 3 months. Here's what the technical charts suggest.
    Copy LinkShare onShare on Share on Share on
    Laurus Labs Ltd. has an average target of 686.25 from 4 brokers.
    logo
    Dr. Reddy's Laboratories Ltd.
    09 Jul 2025
    Acquisition
    1316.70
    1.04%
    Dr Reddy's Labs Dividend: Last Day To Buy Shares And Qualify Before Record Date
    Dr Reddy's Labs Dividend: Last Day To Buy Shares And Qualify Before Record Date
    NDTV Profit
    Dr Reddy's Labs will pay a final dividend of Rs 8 per share for the financial year 2025.
    Copy LinkShare onShare on Share on Share on
    Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.
    Dr. Reddy's Laboratories shares to go ex-dividend tomorrow. Do you own?
    Economic Times | 09 Jul 2025
    logo
    Dr. Reddy's Laboratories Ltd.
    08 Jul 2025
    Acquisition
    1316.70
    1.04%
    Trump Tariffs: Dr Reddy's To Lupin Pharma Stocks To Be In Focus After Threat Of 200% Levies
    Trump Tariffs: Dr Reddy's To Lupin Pharma Stocks To Be In Focus After Threat Of 200% Levies
    NDTV Profit
    Trump's threat of 200% tariff on pharmaceutical products could have severe implications on Indian drugmakers, as exports to the US form a significant share of their overall sales.
    Copy LinkShare onShare on Share on Share on
    Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.
    logo
    Nectar Lifesciences Ltd.
    08 Jul 2025
    15.78
    4.99%
    Nectar Lifesciences hits 52-week low; why are investors dumping stock?
    Business Standard
    Nectar Lifesciences share price hit 52-weel low at 18.6 per share; here's why the stock is under pressure
    Copy LinkShare onShare on Share on Share on
    Nectar Lifesciences Ltd. has lost -35.01% in the last 3 Months
    logo
    Nectar Lifesciences Ltd.
    08 Jul 2025
    15.78
    4.99%
    Nectar to sell API, formulations and menthol biz to Ceph for 1,290 cr
    Business Standard
    Nectar Lifesciences Ltd on Tuesday said it will sell its active pharmaceutical ingredients and formulation along with menthol business assets to Ceph Lifesciences Pvt Ltd, for Rs 1,290 crore. The company has signed a definitive Business Transfer Agreement (BTA) for the sale of its core business division, comprising the manufacture, distribution, and marketing of Active Pharmaceutical Ingredients (APIs) and formulations to Ceph Lifesciences for Rs 1,270 crore on a slump sale basis, Nectar said in a regulatory filing. Additionally, the company has entered into an Asset Purchase Agreement (APA) for the sale of its menthol business assets to Ceph Lifesciences for Rs 20 crore, marking a comprehensive restructuring move aligned with its future strategy, it added. "By divesting mature segments of our business, we are laying the foundation for a focused and agile organisation geared towards innovation and long-term value creation," Nectar Lifesciences Promoter and Chairman Sanjiv Goyal...
    Copy LinkShare onShare on Share on Share on
    Nectar Lifesciences Ltd. has lost -40.16% in the last 6 Months
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd